DALLAS, July 17, 2015 /PRNewswire/ --
ReportsnReports.com adds new market research titled Global Orphan drug Industry Report 2015, to its pharmaceuticals intelligence collection, providing historic data for 2010-2015 and forecasts on the market for 2015-2020.
Complete report on orphan drug market spread across 145 pages, talking about 12 companies and supported with 188 tables and figures is now available at http://www.reportsnreports.com/reports/404412-global-orphan-drug-industry-report-2015.html .
This is a professional and in-depth study on the current state of the Orphan drug market. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Orphan drug market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.
The report focuses on global major leading industry players of the orphan drug market, providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Orphan drug market development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.
With 188 tables and figures to support the orphan drug market analysis, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Companies profiled in this report include Agenus, AOP Orphan, Biogen IDEC, Eli Lilly, Celgene, Alexion, Merck, Roche, Genethon, Pfizer, Bristol Myers Squibb and Genzyme Corporation. Order a copy of global orphan drug market 2015 report at http://www.reportsnreports.com/Purchase.aspx?name=404412 .
Partial list of tables and figures provided to support the orphan drug market analysis in this research covers:
Figure Global and China Sales (K Tonne) and Growth Rate of Orphan drug 2015-2020
Table Global Supply, Sales and Shortage of Orphan drug 2015-2020 (K Tonne)
Table China Supply, Sales and Shortage of Orphan drug 2015-2020 (K Tonne)
Table China Production, Import, Export and Consumption of Orphan drug 2015-2020 (K Tonne)
Table Global Production (K Tonne), Price (USD/Tonne), Cost (USD/Tonne), Revenue (M USD) and Gross Margin of Orphan drug 2015-2020
Table China Production (K Tonne), Price (USD/Tonne), Cost (USD/Tonne), Revenue (M USD) and Gross Margin of Orphan drug 2015-2020
Table Major Raw Materials Suppliers of Orphan drug with Contact Information
Table Manufacturing Equipment Suppliers of Orphan drug with Contact Information
Table Major Suppliers of Orphan drug with Contact Information
Table Key Consumers of Orphan drug with Contact Information
Figure Supply Chain Relationship Analysis of Orphan drug
Table New Project SWOT Analysis of Orphan drug
Table New Project Investment Feasibility Analysis of Orphan drug
Table Part of Interviews
On a related note, another research report titled Orphan Diseases Partnering Terms and Agreements provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the world's leading healthcare companies. Providing information on trends in orphan diseases partnering deals, disclosed headlines, up fronts, milestones and royalties by stage of development, orphan diseases partnering contract documents and top orphan diseases deals by value, this research provides an understanding and analysis of how and why companies enter orphan diseases partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan diseases technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report contains over 90 links to online copies of actual orphan diseases deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In addition, a comprehensive appendix is provided with each report of all orphan diseases partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in orphan diseases partnering and dealmaking since 2009. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of orphan diseases technologies and products. Read more at http://www.reportsnreports.com/reports/219404-orphan-diseases-partnering-terms-and-agreements.html .
Within the pharmaceuticals market, ReportsnReports.com has other 2015 published research reports:
Cystic Fibrosis - Pipeline Review, H1 2015: This report provides comprehensive information on the therapeutic development for Cystic Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cystic Fibrosis and special features on late-stage and discontinued projects. Companies discussed in this research include Actelion Ltd, Alaxia SAS, AlgiPharma AS, Arcturus Therapeutics, Inc, Bayer AG, Beech Tree Labs, Inc., Carolus Therapeutics, Inc., Celsus Therapeutics Plc, Celtaxsys, Inc., Chiesi Farmaceutici SpA, Cilian AG, Concert Pharmaceuticals, Inc., Corbus pharmaceuticals, Inc., Cubist Pharmaceuticals, Inc., DiscoveryBiomed, Inc., Errant Gene Therapeutics, LLC, Galapagos NV, GlaxoSmithKline plc, Grifols, S.A., Invion Limited, InvivoGen Therapeutics, JHL Biotech, Inc., Kamada Ltd., Lamellar Biomedical Ltd, Laurent Pharmaceuticals Inc., Microbion Corporation, Mucokinetica Ltd., N30 Pharmaceuticals, NanoBio Corporation, Nostrum Pharmaceuticals, LLC, Novabiotics Ltd, Novartis AG, Ockham Biotech Limited, OSE Pharma SA, Parion Sciences, Inc., Pfizer Inc., Pharmaxis Limited, Polyphor Ltd., Progenra, Inc., ProQR Therapeutics N.V., Protalix BioTherapeutics, Inc. , PTC Therapeutics, Inc., Pulmatrix, Inc., Reata Pharmaceuticals, Inc., ReveraGen BioPharma, Inc., Serendex Pharmaceuticals A/S, Shire Plc, Synovo GmbH, Verona Pharma Plc,
Vertex Pharmaceuticals Incorporated and Xenetic Biosciences plc. Read more at http://www.reportsnreports.com/reports/345233-cystic-fibrosis-pipeline-review-h1-2015.html .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252